Ascelia Pharma Past Earnings Performance
Past criteria checks 0/6
Ascelia Pharma's earnings have been declining at an average annual rate of -39.7%, while the Biotechs industry saw earnings growing at 16.9% annually.
Key information
-39.7%
Earnings growth rate
-18.7%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | n/a |
| Return on equity | -44.9% |
| Net Margin | n/a |
| Next Earnings Update | 04 Nov 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ascelia Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 0 | -115 | 34 | 104 |
| 31 Mar 22 | 0 | -126 | 35 | 103 |
| 31 Dec 21 | 0 | -126 | 30 | 108 |
| 30 Sep 21 | 0 | -127 | 25 | 102 |
| 30 Jun 21 | 0 | -113 | 22 | 88 |
| 31 Mar 21 | 0 | -111 | 26 | 80 |
| 31 Dec 20 | 0 | -99 | 29 | 65 |
| 30 Sep 20 | 0 | -90 | 29 | 60 |
| 30 Jun 20 | 0 | -88 | 28 | 58 |
| 31 Mar 20 | 0 | -71 | 21 | 51 |
| 31 Dec 19 | 0 | -66 | 19 | 43 |
| 30 Sep 19 | 0 | -46 | 17 | 30 |
| 30 Jun 19 | 0 | -37 | 14 | 23 |
| 31 Mar 19 | 0 | -30 | 15 | 16 |
| 31 Dec 18 | 0 | -23 | 13 | 12 |
| 30 Sep 18 | 0 | -22 | 13 | 10 |
Quality Earnings: ACES is currently unprofitable.
Growing Profit Margin: ACES is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACES is unprofitable, and losses have increased over the past 5 years at a rate of 39.7% per year.
Accelerating Growth: Unable to compare ACES's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACES is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: ACES has a negative Return on Equity (-44.88%), as it is currently unprofitable.